Skip to main content
The William Harvey Research Institute - Faculty of Medicine and Dentistry
  1. WHRI
  2. People
  3. Academic staff
  4. Items

Professor Mauro Perretti

Mauro

Professor of Immunopharmacology

Centre: Biochemical Pharmacology

Email: m.perretti@qmul.ac.uk
Telephone: +44(0) 20 7882 8782

Profile

ORCID iD: 0000-0003-2068-3331

Google Scholar

Degree in Medicinal Chemistry (1985) followed by a Master in Pharmacology and Toxicology (1988), both from the University of Florence, Italy. Doctorate from the University of London in 1996.

Academic path built on two fellowships from Arthritis Research Campaign (career development fellowship and senior fellowship): 1997-2007.

Senior roles: Deputy Director of William Harvey Research Institute (2006-2013); Co-Director of William Harvey Research Institute (2013-2016); Dean for Research and Research Impact of the Faculty of Medicine and Dentistry (2015-2022).

 

Research

Group members

Dr Magdalena KANEVA (senior post-doctoral fellow), Dr Chiara CECCONELLO (post-doctoral fellow), Dr Michele SUGIMOTO (post-doctoral fellow), Miss Marilena CHRISTOFOROU (PhD student), Mr Weifeng BU (PhD Student), Dr Hedayatullah HAYAT (QMUL/CARA Fellow), Miss Ayda Henriques SCHNEIDER (FAPESP Fellow).

Summary

Prof Perretti expertise are in the area of pathophysiology of inflammation with a strong attention to therapeutic opportunities. He has pioneered the studies on the biology of the Resolution of Inflammation, its mechanisms and mediators. Currently, Mauro and his team collaborate with commercial partners to establish resolution pharmacology, as a new branch where novel therapies could be developed on the science of resolution.

Publications

  • Chen J, Keswich JE, Chiazza F et al. (2026). Correction to: IkB Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD.. nameOfConference


    QMRO: qmroHref
  • Khodeneva N, Davan-Wetton CSA, Jonassen TEN et al. (publicationYear). The anti-inflammatory efficacy of melanocortin drugs is influenced by genetic variation at MC1R. nameOfConference


  • Nyi TH, Rivellese F, Pitzalis C et al. (2026). Unravelling early myocardial changes in rheumatoid arthritis by cardiovascular magnetic resonance: insights from the UK biobank. nameOfConference


  • Christoforou M, Chen J, Cooper D et al. (2026). Interleukin-6 blockade modulates monocyte recruitment to protect against diastolic dysfunction associated with inflammatory arthritis. nameOfConference


  • Perretti M, Montero-Melendez T (2025). Resolution Pharmacology: State-of-the-art and therapeutic landscape. nameOfConference


  • Davan-Wetton CS, Khodeneva N, Denton CP et al. (2025). The senescence-like activity of BMS-470539 is associated with anti-fibrotic actions in models of dermal fibrosis. nameOfConference


  • Hussain MT, Austin‐Williams S, McCay J et al. (2025). Comparative Assessment of Whole Organ Tissue Processing Methods for the Isolation of Extracellular Vesicles From Intact Organs. nameOfConference


  • Margraf A, Chen J, Christoforou M et al. (2025). Formyl-peptide receptor type 2 activation mitigates heart and lung damage in inflammatory arthritis. nameOfConference


  • Lara ES, Carvalho AFS, Cardoso C et al. (2025). Annexin A1/FPR2 pathway modulates leukocyte function during Escherichia coli‐induced pneumonia to promote resolution of inflammation and restores lung function. nameOfConference


  • Oggero S, Voisin M-B, Picco F et al. (2025). Activation of proresolving macrophages in dorsal root ganglia attenuates persistent arthritis pain. nameOfConference


View profile publication page

Sponsors

Funders

Commercial partnerships

Collaborators

Internal

External

  • Dr Stanly Fan (Barts Health NHS Trust)
  • Prof Sandra Farsky (University of Sao Paulo, Brazil)
  • Prof Catherine Godson (University College Dublin, Ireland)
  • Dr Andreas Margraf (University of Münster, Germany)
  • Dr Patricia Martins Silva (FioCruz, Rio de Janeiro, Brazil)
  • Prof Chris Reutelingsperger (University of Maastricht, Netherlands)
  • Prof Mauro M Teixeira (Federal University of Minas Gerais, Brazil)

News

Teaching

  • Lectures on receptor theory, inflammatory models and resolution of inflammation to undergraduate students (P&IT) and post-graduate students (BHF DTP).
  • Assessor for student selected component years 2 and 4.

Disclosures

  • Shareholder (ResoTher Pharma AS; Antibe Therapeutics)
  • Scientific Advisory Board Member (SynAct Pharma, ResoTher Pharma)
  • Director (William Harvey Research Limited)
  • Consultancies (SynAct Pharma, BMS, Palatin Technologies)
  • Collaborative Projects (TXP Pharma, BMS, BioAegis)

Back to top